Seeking Alpha

Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its...

Jefferies says Jazz Pharmaceuticals' (JAZZ +16.6%) acquisition of EUSA will add $0.76 to its FY13 earnings estimate and diversifies the company away from Xyrem. The firm now calls Jazz one of its top picks and raises its price target to $74.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)